Technical Analysis for ARGX - argenx SE

Grade Last Price % Change Price Change
grade D 228.83 0.27% 0.61
ARGX closed up 0.27 percent on Tuesday, August 11, 2020, on 1.13 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical ARGX trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Down 3 Days in a Row Weakness 0.27%
Down 4 Days in a Row Weakness 0.27%
Down 5 Days in a Row Weakness 0.27%
Oversold Stochastic Weakness 0.27%
Calm After Storm Range Contraction -0.84%
Down 3 Days in a Row Weakness -0.84%
Down 4 Days in a Row Weakness -0.84%
Oversold Stochastic Weakness -0.84%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Biopharmaceutical Cancer Immunotherapy Solid Tumors Autoimmune Diseases Acute Myeloid Leukemia Rheumatoid Arthritis Myelodysplastic Syndrome Treatment Of Autoimmune Diseases Hematological Cancers Dyslipidemia Myasthenia Gravis Tolerx Janus Kinase Inhibitor Treatment Of Hematological Cancers Abbvie Inc.

Is ARGX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 272.74
52 Week Low 103.75
Average Volume 189,014
200-Day Moving Average 170.02
50-Day Moving Average 236.63
20-Day Moving Average 246.33
10-Day Moving Average 233.40
Average True Range 8.44
ADX 25.08
+DI 21.15
-DI 29.39
Chandelier Exit (Long, 3 ATRs ) 247.42
Chandelier Exit (Short, 3 ATRs ) 250.12
Upper Bollinger Band 274.66
Lower Bollinger Band 218.01
Percent B (%b) 0.19
BandWidth 23.00
MACD Line -2.39
MACD Signal Line 1.26
MACD Histogram -3.6475
Fundamentals Value
Market Cap 6.15 Billion
Num Shares 26.9 Million
EPS -1.27
Price-to-Earnings (P/E) Ratio -180.18
Price-to-Sales 15.41
Price-to-Book 3.49
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 235.55
Resistance 3 (R3) 235.69 233.59 234.43
Resistance 2 (R2) 233.59 231.88 233.52 234.06
Resistance 1 (R1) 231.21 230.82 230.16 231.07 233.68
Pivot Point 229.11 229.11 228.59 229.04 229.11
Support 1 (S1) 226.73 227.40 225.68 226.59 223.98
Support 2 (S2) 224.63 226.34 224.56 223.60
Support 3 (S3) 222.25 224.63 223.23
Support 4 (S4) 222.11